Loading…

Coronado's inflammatory bowel disease treatment fails mid-stage study

Oct 14 (Reuters) – Coronado Biosciences Inc said its treatment for Crohn's disease, a type of inflammatory bowel disease, failed to meet the main goal of a mid-stage study. The company said the response rate of patients with moderate-to-severe Crohn's